Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
Nirmatrelvir/ritonavir is approved for the treatment of adults and pediatric patients with mild to moderate COVID-19, but information on adverse events associated with its use is limited. We aim to evaluate adverse events with potential risk for nirmatrelvir/ritonavir using the FDA Adverse Event Rep...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , |
|---|---|
| Формат: | Ном |
| Хэвлэсэн: |
MDPI AG,
2022-11-01T00:00:00Z.
|
| Нөхцлүүд: | |
| Онлайн хандалт: | Connect to this object online. |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Интернэт
Connect to this object online.3rd Floor Main Library
| Зохиогчийн тэмдэгт: |
A1234.567 |
|---|---|
| Хуулбар 1 | Бэлэн |